Ameritas Advisory Services’s Adaptive Biotechnologies ADPT Stock Holding History

Ameritas Advisory Services’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-200	Closed	-$1.77K	–	572
2023 Q1	$1.77K	Buy	+200	New	+$1.76K	﹤0.01%	2424

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AAP

Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Ameritas Advisory Services's ADPT Position: Q2 2023 in Review

Ameritas Advisory Services sold out of Adaptive Biotechnologies (ADPT) in Q2 2023, closing a stake of 200 shares — an estimated $1.77K sold.

Ameritas Advisory Services first reported a position in ADPT in Q1 2023 and held it in 1 quarter. The position peaked at $1.77K in Q1 2023. 210 funds tracked by Wall St. Rank hold ADPT as of Q2 2023.

Ameritas Advisory Services reported no remaining Adaptive Biotechnologies position as of Q2 2023 after selling out during the quarter.
Ameritas Advisory Services sold 200 Adaptive Biotechnologies shares in Q2 2023, an estimated $1.77K.
Ameritas Advisory Services first reported a position in Adaptive Biotechnologies in Q1 2023 and held it in 1 quarter.
Ameritas Advisory Services's Adaptive Biotechnologies position peaked at $1.77K in Q1 2023.
210 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2023.

Based on Ameritas Advisory Services's 13F filing for Q2 2023, filed 25 Jul 2023.